Clinical Trials · NCT06734130
Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer
- Phase
- Phase 2
- Recruitment status
- Active Not Recruiting
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Enrollment
- 25
- Start date
- Jan 2025
- Locations
- 1 site, United States
- Primary endpoint
- Castration Sensitivity Rate